{"studyId":"rcc_iatlas_immotion150_2018","cancerTypeId":"rcc","name":"Renal Cell Carcinoma (IMmotion150 Clinical Trial, Nat Med. 2018) - iAtlas Harmonized","description":"A randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 263 patients with treatment-naive metastatic renal cell carcinoma. The reprocessing of raw sequencing data is coordinated by <a href=\"https://cri-iatlas.org/\">CRI iAtlas</a>.","publicStudy":true,"pmid":"29867230","citation":"McDermott et al. Nat Med 2018","groups":"","status":1,"importDate":"2026-02-11 00:49:06","allSampleCount":263,"sequencedSampleCount":158,"cnaSampleCount":0,"mrnaRnaSeqSampleCount":263,"mrnaRnaSeqV2SampleCount":0,"mrnaMicroarraySampleCount":0,"miRnaSampleCount":0,"methylationHm27SampleCount":0,"rppaSampleCount":0,"massSpectrometrySampleCount":0,"completeSampleCount":0,"referenceGenome":"hg38","treatmentCount":0,"structuralVariantCount":0,"cancerType":{"id":"rcc","name":"Renal Cell Carcinoma","dedicatedColor":"Orange","shortName":"RCC","parent":"kidney"},"readPermission":true,"resourceCounts":[]}